Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
Holding BIO?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$2.87Last Year’s EPS
$3.1Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: -0.94%
|Next Earnings Date:Feb 13, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive developments, such as strong performance in Clinical Diagnostics and improved gross margins, alongside challenges in the Life Science segment and geographic markets like Asia Pacific. Operational efficiencies and cost management initiatives have been beneficial, but headwinds in certain market segments persist.Company Guidance
During Bio-Rad's Q3 2024 earnings call, the executives provided several key metrics and guidance figures. The company reported net sales of $650 million, marking a 2.8% increase from the previous year. On a currency-neutral basis, this represented a 3.4% increase, driven primarily by a 5.6% growth in the Clinical Diagnostics segment. The Life Science group, however, remained essentially flat with sales of approximately $261 million. Bio-Rad's non-GAAP gross margin improved to 55.6%, up from 53.9% in Q3 2023, attributed to revenue mix and productivity enhancements. For the full year 2024, Bio-Rad maintained its revenue guidance, anticipating a 2.5% to 4% decline year-over-year on a currency-neutral basis. The company also increased its full-year non-GAAP gross margin guidance to between 55% and 55.5% and its non-GAAP operating margin to between 12.75% and 13.25%. Adjusted EBITDA margin is expected to be between 18.5% and 19% for the year. Additionally, Bio-Rad's free cash flow for 2024 is projected to be approximately $300 million, up from $218 million in 2023.Clinical Diagnostics Growth
Clinical Diagnostics group revenue increased by 5.6% on a reported basis and 6.4% on a currency-neutral basis, primarily driven by demand for quality control products.
Gross Margin Improvement
Reported GAAP gross margin improved to 54.8% from 53.1% in the previous year, driven by improved productivity, lower logistics costs, and revenue mix.
Strong Free Cash Flow
Free cash flow for Q3 2024 was approximately $123 million, compared to $54 million in Q3 2023.
Positive Droplet Digital PCR Performance
Droplet Digital PCR franchise grew mid-single digits, driven by ongoing interest in new assays for oncology and cell and gene therapy markets.
---
BIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $330.58 | $358.19 | +8.35% |
| Aug 01, 2024 | $341.25 | $335.93 | -1.56% |
| May 07, 2024 | $279.91 | $268.26 | -4.16% |
| Feb 15, 2024 | $328.73 | $340.52 | +3.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bio-Rad Laboratories (BIO) report earnings?
Bio-Rad Laboratories (BIO) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Bio-Rad Laboratories (BIO) earnings time?
Bio-Rad Laboratories (BIO) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BIO EPS forecast?
BIO EPS forecast for the fiscal quarter 2024 (Q4) is $2.87.
---